<p><strong>Pediatric Use</strong>:&nbsp;Safety and effectiveness in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>:&nbsp;Clearance of ticlopidine is somewhat lower in elderly patients and trough levels are increased. The major clinical trials with Ticlopidine in stroke patients were conducted in an elderly population with an average age of 64 years. Of the total number of patients in the therapeutic trials, 45% of patients were over 65 years old and 12% were over 75 years old. No overall differences in effectiveness or safety were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.<br />
<br />
<strong>Renal Impairment</strong>: Dose reduction or discontinuance if haemorrhagic or haematopoietic complications occur.<br />
<br />
<strong>Hepatic Impairment</strong>: Severe: contraindicated.</p>